TÜBINGEN, GERMANY — Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR study....
No actionable change — these are top-line Phase 2a results from a company press release with no peer-reviewed data available yet; audiologists should monitor for future published trial data.
If confirmed in larger trials, a drug that prevents chemotherapy-related hearing damage (ototoxicity) could significantly reduce one of the most common and life-altering side effects of cisplatin-based cancer treatment.
- 01Acousia Therapeutics announced positive top-line Phase 2a results for ACOU085 (Bimokalner) from the PROHEAR study.
- 02The drug targets prevention of cisplatin-induced ototoxicity (hearing damage caused by chemotherapy).
- 03This is a first-in-patient Phase 2a result — early human safety and efficacy data only.
- 04Results were announced via press release; no peer-reviewed publication has been cited.
- 05Further larger trials would be needed before any clinical adoption is possible.
ACOU085 (Bimokalner) produced positive top-line Phase 2a efficacy results in preventing cisplatin-induced ototoxicity.
press releasepromotionalACOU085 is the first drug evaluated in patients specifically for cisplatin-induced ototoxicity prevention in this trial.
press releaseunclear